HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goodwin, D. A. Articles by Chaovapong, W. Search for Related Content PubMed PubMed Citation Articles by Goodwin, D. A. Articles by Chaovapong, W.

Chelate Conjugates of Monoclonal Antibodies for Imaging Lymphoid Structures in the Mouse

Nuclear Medicine Service, Veterans Administration Medical Center, Palo Alto; Stanford University School of Medicine, Stanford; and Department of Chemistry, University of California, Davis, California

Correspondence: For reprints contact: David A. Goodwin, MD, VA Medical Center, 3801 Miranda Ave., Palo Alto, CA 94304.

ABSTRACT

Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA^k expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti () IA^k MoAb with purified, no-carrier-added ¹¹¹ln citrate. Labeling efficiency was 85–95%, and the labeled IA^k MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered ¹¹¹lnlA^k MoAb was compared in mice, two IA^k positive and one IA^k negative strains, and to ¹²⁵llA^k MoAb in one IA^k positive strain. The ¹¹¹lnlA^k MoAb was more stable in vivo compared to ¹²⁵llA^k MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of ¹¹¹ln lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.